ARB and cardioprotection

Cardiovascular Drugs and Therapy

Volumn 27, Issue 2, 2013, Pages 155-160

  Akazawa, Hiroshi ^a,b   Yabumoto, Chizuru ^a   Yano, Masamichi ^a   Kudo Sakamoto, Yoko ^a   Komuro, Issei ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cardiac remodeling; Constitutive activity; G protein coupled receptor; Inverse agonist; Mechanical stress

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; LOSARTAN; OLMESARTAN;

ARTICLE; CARDIAC REMODELING; CONFORMATIONAL TRANSITION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HEART DISEASE; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; VENTRICULAR REMODELING;

EID: 84878306068     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6392-2     Document Type: Article

References (47)

1. Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2004;1:42-7.
2. Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev. 2006;86:747-803.
3. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-51.
4. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem. 1998;273:17979- 82.
5. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev. 2000;21:90-113.
6. Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res. 2003;26:937-43.
7. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the reninangiotensin- aldosterone system. Nat Rev Drug Discov. 2002;1:621- 36.
8. Dell'italia LJ. Translational success stories: Angiotensin receptor 1 antagonists in heart failure. Circ Res. 2011;109:437-52.
9. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
10. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep. 2008;9:179-86.
11. Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, et al. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation. Hypertens Res. 2009;32:875-83.
12. Akazawa H, Yasuda N, Komuro I. Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor. Mol Cell Endocrinol. 2009;302:140-7.
13. Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, et al. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension. 2012;59:627-33.
14. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6:499-506.
15. Mederos y Schnitzler M, Storch U, Meibers S, Nurwakagari P, Breit A, Essin K, et al. Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J. 2008;27:3092- 103.
16. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;3:ra46.
17. Strange PG. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci. 2002;23:89-95.
18. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: A current perspective. Mol Pharmacol. 2003;64:1271-6.
19. Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci. 2006;27:92-6.
20. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-9.
21. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am J Hypertens. 1992;5:276-80.
22. Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A. 1997;94:6391-6.
23. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A. 2000;97:931-6.
24. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6.
25. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491- 8.
26. Ogihara T, Fujimoto A, Nakao K, Saruta T. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther. 2008;6:1195-201.
27. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
28. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953-70.
29. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 1995;77:258-65.
30. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996;271:33592-7.
31. Kudoh S, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiojima I, et al. Angiotensin II stimulates c-Jun NH2-Terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res. 1997;80:139- 46.
32. Nishida M, Tanabe S, Maruyama Y, Mangmool S, Urayama K, Nagamatsu Y, et al. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2-Terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem. 2005;280:18434-41.
33. Bueno OF, Molkentin JD. Involvement of extracellular signalregulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91:776-81.
34. Hunyady L, Turu G. The role of the AT1 angiotensin receptor in cardiac hypertrophy: Angiotensin II receptor or stretch sensor? Trends Endocrinol Metab. 2004;15:405-8.
35. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 2006;281:19288- 95.
36. Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest. 2007;117:1914-25.
37. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439- 47.
38. Fujii N, Tanaka M, Ohnishi J, Yukawa K, Takimoto E, Shimada S, et al. Alterations of angiotensin II receptor contents in hypertrophied hearts. Biochem Biophys Res Commun. 1995;212:326- 33.
39. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:46-54.
40. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993;55:55-75.
41. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551-71.
42. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9.
43. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-84.
44. Yamano Y, Ohyama K, Chaki S,Guo DF, Inagami T. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem Biophys Res Commun. 1992;187:1426-31.
45. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994;269:31334-7.
46. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol. 2008;22:139-46.
47. Fujino M, Miura S, Kiya Y, Tominaga Y, Matsuo Y, Karnik SS, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT receptor-dependent and -independent beneficial effects. Hypertens Res. 2010;33:1044-52.